Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Naehrig

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Deutsches Arzteblatt International|September 1, 2017
Cystic FibrosisSusanne Naehrig, Cho-Ming Chao, Lutz Naehrlich
BMC Pulmonary Medicine|June 14, 2020
An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosaSivagurunathan Sutharsan, Susanne Naehrig, Uwe Mellies, et al.
European Journal of Medical Research|April 6, 2011
Lung function in adult patients with cystic fibrosis after using the eFlow rapid for one yearSusanne Naehrig, S Lang, H Schiffl, et al.
Respiratory Physiology & Neurobiology|August 2, 2016
Multi-layer ventilation inhomogeneity in cystic fibrosisSabine Krueger-Ziolek, Benjamin Schullcke, Zhanqi Zhao, et al.
Pediatric Pulmonology|July 6, 2016
Eradication of methicillin resistant Staphylococcus aureus detected for the first time in cystic fibrosis: A single center observational studyMatthias Kappler, Felicitas Nagel, Maria Feilcke, et al.
Journal of Personalized Medicine|October 25, 2024
Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic FibrosisSusanne Naehrig, Christina Shad, Magdalena Breuling, et al.
The Lancet Regional Health. Europe|August 9, 2023
Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF RegistrySivagurunathan Sutharsan, Stefanie Dillenhoefer, Matthias Welsner, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Deutsches Arzteblatt International|September 1, 2017
Cystic FibrosisSusanne Naehrig, Cho-Ming Chao, Lutz Naehrlich
BMC Pulmonary Medicine|June 14, 2020
An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosaSivagurunathan Sutharsan, Susanne Naehrig, Uwe Mellies, et al.
European Journal of Medical Research|April 6, 2011
Lung function in adult patients with cystic fibrosis after using the eFlow rapid for one yearSusanne Naehrig, S Lang, H Schiffl, et al.
Respiratory Physiology & Neurobiology|August 2, 2016
Multi-layer ventilation inhomogeneity in cystic fibrosisSabine Krueger-Ziolek, Benjamin Schullcke, Zhanqi Zhao, et al.
Pediatric Pulmonology|July 6, 2016
Eradication of methicillin resistant Staphylococcus aureus detected for the first time in cystic fibrosis: A single center observational studyMatthias Kappler, Felicitas Nagel, Maria Feilcke, et al.
Journal of Personalized Medicine|October 25, 2024
Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic FibrosisSusanne Naehrig, Christina Shad, Magdalena Breuling, et al.
The Lancet Regional Health. Europe|August 9, 2023
Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF RegistrySivagurunathan Sutharsan, Stefanie Dillenhoefer, Matthias Welsner, et al.
Pageof 1